SciNeuro Pharmaceuticals and Novartis have signed a global license and collaboration agreement to develop a new anti-amyloid beta antibody program for the treatment of Alzheimer's disease.[1] Novartis will acquire global rights to this potentially disease-modifying anti-amyloid antibody, which uses SciNeuro's proprietary shuttle platform for delivery to the brain.[1] The deal was announced at the start of J.P. Morgan Healthcare Conference.[1] Novartis will pay $165 million upfront for the right to collaborate on the early development of the program.[1] Later, Novartis will take over later clinical and product development as well as global commercialization.[1] SciNeuro may receive up to $1.5 billion in development, regulatory and commercialization milestones, plus tiered royalties.[1] The program is called SNP234 and offers potential differentiation from existing agents targeting amyloid beta.[1] The transaction is expected to close in the first half of this year.[1]